Summarize this content to 100 words
April 23, 2024
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
“
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio
Key takeaways:
The FDA issued a complete response letter based on lack of information on certain manufacturing and release testing methods.
Abeona plans to resubmit its application in the third quarter of 2024.
The FDA did not approve Abeona Therapeutics’ biologics license application for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa, the company announced in a press release.
During a late cycle review meeting in March as well as in a subsequent information request, the FDA informed Abeona Therapeutics that certain additional data were needed to satisfy chemistry manufacturing and controls (CMC) requirements before the application for prademagene zamikeracel (pz-cel) for recessive dystrophic epidermolysis bullosa (RDEB) could be approved.
The FDA did not approve Abeona Therapeutics’ biologics license application for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa. Image: Adobe Stock.
After submitting a plan to provide the CMC data, the FDA issued a complete response letter (CRL) stating that the proposed timing of the data submission would not allow sufficient time to complete its review by the PDUFA date on May 25.
“While we are surprised and disappointed by this CRL, we are committed to providing the CMC information necessary to respond to the agency’s asks, with the goal of bringing pz-cel to patients with RDEB as quickly as possible,” Vishwas Seshadri, MBA, CEO of Abeona, said in the release.
According to the press release, the additional data needed to fulfill the CMC requirements include information on certain manufacturing and release testing methods. The company has pointed out that the FDA did not identify any problems related to pz-cel’s efficacy or safety.
Abeona Therapeutics shares fell 53% just hours after its application for pz-cel was denied approval. Nevertheless, the company remains optimistic about the future of pz-cel for RDEB.
“We anticipate completing the BLA resubmission in the third quarter of 2024 with necessary updates to fully satisfy all the deficiencies outlined in the CRL,” Seshadri said.
Reference:
Published by:
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
“
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio